SG11202109568TA - Pyridazinones and methods of use thereof - Google Patents

Pyridazinones and methods of use thereof

Info

Publication number
SG11202109568TA
SG11202109568TA SG11202109568TA SG11202109568TA SG 11202109568T A SG11202109568T A SG 11202109568TA SG 11202109568T A SG11202109568T A SG 11202109568TA SG 11202109568T A SG11202109568T A SG 11202109568TA
Authority
SG
Singapore
Prior art keywords
pyridazinones
methods
Prior art date
Application number
Other languages
English (en)
Inventor
John Reilly
Liron Walsh
Peter Mundel
Amy Westerling-Bui
Matthew Daniels
Maolin Yu
Mark Ledeboer
Jean-Christophe Harmange
Gal Marie-Francoise Coeffet-Le
Michael Broxson
Original Assignee
Goldfinch Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldfinch Bio Inc filed Critical Goldfinch Bio Inc
Publication of SG11202109568TA publication Critical patent/SG11202109568TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
SG11202109568T 2019-03-20 2020-03-18 Pyridazinones and methods of use thereof SG11202109568TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962821178P 2019-03-20 2019-03-20
PCT/US2020/023369 WO2020191056A1 (fr) 2019-03-20 2020-03-18 Pyridazinones et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
SG11202109568TA true SG11202109568TA (en) 2021-10-28

Family

ID=72519163

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109568T SG11202109568TA (en) 2019-03-20 2020-03-18 Pyridazinones and methods of use thereof

Country Status (10)

Country Link
US (1) US20220152031A1 (fr)
EP (1) EP3941475A4 (fr)
CN (1) CN113939295A (fr)
AU (1) AU2020240059A1 (fr)
CA (1) CA3132580A1 (fr)
IL (1) IL286481A (fr)
MA (1) MA55381A (fr)
MX (1) MX2021011316A (fr)
SG (1) SG11202109568TA (fr)
WO (1) WO2020191056A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3852533B8 (fr) * 2018-09-18 2024-07-17 Gfb (Abc), Llc Pyridazinones et leurs procédés d'utilisation
KR20230028522A (ko) * 2020-07-03 2023-02-28 우한 엘엘 사이언스 앤드 테크놀로지 디벨롭먼트 컴퍼니, 리미티드 헤테로고리 화합물 및 이의 용도
JP2024533411A (ja) * 2021-09-10 2024-09-12 メッドシャイン ディスカバリー インコーポレイテッド ハロゲン置換のピリダジノン系化合物及びその使用
CN114235972B (zh) * 2021-10-28 2023-08-22 乳源东阳光药业有限公司 一种测定利格列汀杂质rbp-1含量的方法
WO2024027752A1 (fr) * 2022-08-05 2024-02-08 武汉朗来科技发展有限公司 Composition pharmaceutique comprenant un composé hétérocyclique, procédé de préparation associé et utilisation correspondante

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2945857A (en) * 1955-05-06 1960-07-19 Monsanto Chemicals Pyridazinones
GB8901423D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
GB9015764D0 (en) * 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
CA2099743A1 (fr) * 1992-07-02 1994-01-03 Akihiko Ishida Derives de la pyridazinone et procedes pour leur preparation
EP0737193A1 (fr) * 1993-12-29 1996-10-16 Fujisawa Pharmaceutical Co., Ltd. Compose pyrazolopyridine antagoniste de l'adenosine
JPH09216883A (ja) * 1996-02-09 1997-08-19 Fujisawa Pharmaceut Co Ltd ピラゾロピリジン化合物および該化合物を含有する医薬
AUPQ441499A0 (en) * 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
US20050043315A1 (en) * 2002-01-02 2005-02-24 Hideo Tsutsumi Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
AU2003901647A0 (en) * 2003-04-04 2003-05-01 Fujisawa Pharmaceutical Co., Ltd. Novel Condensed Furan Compounds and Pharmaceutical Use Thereof
US20050165032A1 (en) * 2004-01-23 2005-07-28 Norman Mark H. Vanilloid receptor ligands and their use in treatments
WO2006044504A1 (fr) * 2004-10-13 2006-04-27 Merck & Co., Inc. Antagonistes aux récepteurs de cgrp
CN101232885A (zh) * 2005-01-25 2008-07-30 神经能质公司 经取代的哒嗪基喹啉-4-基胺和嘧啶基喹啉-4-基胺类似物
RU2396269C2 (ru) * 2005-12-01 2010-08-10 Ф.Хоффманн-Ля Рош Аг Производные гетероарилзамещенного пиперидина в качестве ингибиторов печеночной карнитин пальмитоилтрансферазы (l-cpt1)
US20090227588A1 (en) * 2005-12-05 2009-09-10 Roman Wolfgang Fleck Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007061963A1 (de) * 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
WO2009114677A1 (fr) * 2008-03-13 2009-09-17 Bristol-Myers Squibb Company Dérivés de la pyridazine inhibiteurs du facteur xia
WO2009117157A1 (fr) * 2008-03-20 2009-09-24 Amgen Inc. Modulateurs d’aurora kinase et procédé d’utilisation
DE102008062826A1 (de) * 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
TW201444844A (zh) * 2013-03-14 2014-12-01 Hydra Biosciences Inc 經取代之黃嘌呤及使用其之方法
EP2881390A1 (fr) * 2013-12-04 2015-06-10 Sanofi Dérivés de thienométhylpipérazine en tant qu'inhibiteurs d'époxyde-hydrolase soluble
JP6667093B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピリド［２，３−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体
WO2019055966A2 (fr) * 2017-09-18 2019-03-21 Goldfinch Bio, Inc. Pyridazinones et leurs procédés d'utilisation

Also Published As

Publication number Publication date
CA3132580A1 (fr) 2020-09-24
MA55381A (fr) 2022-01-26
JP2022525506A (ja) 2022-05-17
US20220152031A1 (en) 2022-05-19
AU2020240059A1 (en) 2021-10-28
CN113939295A (zh) 2022-01-14
WO2020191056A8 (fr) 2021-09-30
MX2021011316A (es) 2021-10-13
WO2020191056A1 (fr) 2020-09-24
EP3941475A1 (fr) 2022-01-26
EP3941475A4 (fr) 2023-01-25
IL286481A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
EP3684364A4 (fr) Pyridazinones et leurs procédés d'utilisation
IL281438A (en) Pyridazinones and methods of using them
IL286481A (en) Pyridazinones and methods of using them
IL287751A (en) kcnt1 inhibitors and methods of use
IL287768A (en) kcnt1 inhibitors and methods of use
IL287973A (en) acss2 inhibitors and methods of their use
IL283387A (en) Diarylhydantoin compounds and methods of use thereof
IL276135A (en) Preparations and methods of use
IL283782A (en) Analosomes and methods of use
IL281866A (en) Devices and methods of introduction into the body and their use
ZA202100780B (en) Bismuth-thiol compositions and methods of use
EP3849664C0 (fr) Composés phénoxy-pyridyl-pyrimidine et méthodes d'utilisation associées
EP3761989A4 (fr) Imidazodiazépinediones et leurs procédés d'utilisation
IL280000A (en) Formulations for reducing tumors and methods of using them
IL276053A (en) Therapeutic Gard and methods of its use
EP3765485A4 (fr) Immuno-exosomes et leurs procédés d'utilisation
IL283231A (en) dpep-1 binding factors and methods of use
GB2589398B (en) Compounds and methods of use
IL276792A (en) Inhaler and methods for using it
ZA201908276B (en) Charge-tagged nucleotides and methods of use thereof
EP3836966A4 (fr) Anticorps catalytiques et leurs méthodes d'utilisation
EP3849663C0 (fr) Composés pyrimidinyl-hétéroaryloxy-naphtyle et procédés d'utilisation
GB201900741D0 (en) Liver-specifc inducible prometers and methods of use thereof
GB201908573D0 (en) Compounds and methods of use